Navigation Links
TeleRehab™ Advantage

ProductsTeleRehab™ Advantage
Company ScottCare Corporation
Item TeleRehab™ Advantage
Features 
  • Single patient outcomes: Illustrates a patients progress
  • Tracks resting and exercise data
  • Collects and compares clinical, behavioral and health data at 6 and 12 months after program completion
  • Single patient outcomes will display up to five user defined numeric data items
  • Group outcomes: generates three reports physiological and behavioral analysis, statistical analysis and certification report
  • group outcomes provides the flexibility to select any one or a combination of pre-established criteria, as well as the ability to define your own criteria to sort your patient population
Description TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outcomes.
Info ScottCare Corporation
Customer Service: (800) 243-9412
Web site: http://www.scottcare.com/index.html

Related medicine products :

1. XL Advantage 3.5x @ 34cm working distance
2. XL Advantage Prismatic
3. XL Advantage 3.5x @ 46cm working distance
4. XL Advantage 4.5x @ 34cm working distance
5. XL Advantage 4.5x @ 42cm working distance
6. XL Advantage 4.5x @ 46cm working distance
7. XL Advantage 5.5x @ 34cm working distance
8. XL Advantage 5.5x @ 42cm working distance
9. XL Advantage 5.5x @ 46cm working distance
10. MultiWash Advantage
11. XL Advantage
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products:
(Date:12/3/2008)...e American College of Surgeons (ACS) today recogni...tee report on resident duty hours that was release...imizing Graduate Medical Trainee (Resident) Hours ... , ACS agrees with the IOM in its conclusion...ork week (averaged over four weeks) are not advisa...
(Date:12/3/2008)... -- Forest Laboratories, Inc. (NYSE: FRX ) today...ited mini-tender offer by TRC Capital Corporation ...pany. Forest Laboratories has received a copy of ...standing shares of the company,s common stock, whi...ing shares. The offer price of $20.35 per share r...
(Date:12/3/2008)...stCall/ -- MAP,Pharmaceuticals, Inc. (Nasdaq: M...icipate in a panel discussion titled "Adapting Spe...he 2008 RBC Capital Markets Healthcare Conference ... in New York City. , A live webcast of the ...,Relations section of MAP Pharmaceuticals, websit...
(Date:12/3/2008)...l-free recombinant albumin product manufactured by... serum in CHO cell culture. , ...Cellastim has proven to be a robust replacement fo...ve both the growth kinetics and productivity of CH...d media. , , ,Studies support InVitria,s claim tha...
Breaking Medicine News(10 mins):Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2
...ef new studies point in the direction that a dose ...breast cancer.// "High levels of daily stress are ...ncer". According to a study carried out at the Nat...h, Copenhagen. A group of over 6,500 women were fo...
...ng is responsible for checking the profits and saf...s sell to the NHS. They have to monitor that only ...ces should be reasonable. The Pharmaceutical Pric...y organization which monitors and legislates the a...
...tents, placement of stents that release the medica...e-narrowing nine months following angioplasty for ...ording to an article in the September 14 issue of ...nized the treatment of atherosclerotic coronary ar...
...ons have come up with a disaster-planning guide to...frequented by tropical storms, hurricanes, tidal w...n the world, people are vulnerable to some sort of...rthquake, flood, hurricane, or tornado. In additio...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Stents That Release Medication To Check Artery Narrowing 2Health News:Disaster Planning Guide From Harvard Health Publications 2
(Date:12/3/2008)...n, a contract development and,manufacturing organ...ined a,strategic financial partner to help it exp...d for Isogen,s services. , Isogen has previ... capital,investment and the opening of its first ...e previously unmet process, facility and capacity ...
(Date:12/3/2008)...stCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ) today ...,manufacturing and control process descriptions (C... move forward with the development of Menerba,(fo... "We have concluded three CMC discussions wi...s recommendations for further development of Mener...
(Date:12/2/2008)... Researchers using functional,MRI (fMRI) have det...n,responsible for suppressing memory is dysfuncti...ychiatric disorders. Results of the study will be ...ological Society of North America,(RSNA). , ...ress-related disorders,traumatic memories are a ...
(Date:12/2/2008)...Call/ -- Biopure Corporation,(Nasdaq: BPUR ) an... Center,(NMRC) has submitted to the Food and Drug...ew drug (IND) application to conduct a clinical tr...R) [hemoglobin glutamer - 250 (bovine)],for the p...ts. The study is,entitled "Operation Restore Effe...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3BioReliance Corporation Launches iNet 28TM 29 for Online Results Tracking of Biological Safety Tests 641 1BioReliance Corporation Launches iNet 28TM 29 for Online Results Tracking of Biological Safety Tests 641 2ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 1ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 2ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 3Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 1Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 2Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 3Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 4Wellcorps International Unveils New Nutritional Supplements 1444 1Wellcorps International Unveils New Nutritional Supplements 1444 2
...ernational Symposium,of Thrombosis and Haemostasis...Baxter,Healthcare Corporation today announced the ...of Data from ADVATE(R) Prospective Trials),study p...t,relationship between the duration of time spent ...nal unit per deciliter (1 IU/dL,one percent of no...
...-- Phase 3 results,from the RE-NOVATE(TM) trial de...ly, administered for an average of 33 days, was,no... average of 33,days, in preventing venous thromboe...hip replacement surgery. In this trial, the,rate o...ate was,similar to enoxaparin. The incidence of li...
Other Medicine Technology:Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 2Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 3Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 4Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 5Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5